Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulumimab plus CAPOX, immunonutrition and probiotics as conversion therapy for advanced gastric/GEJ adenocarcinoma
ChiCTR2600123343Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sulumimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, metastatic malignant neoplasm in lymph node (LNM) and 1 more, sponsored by Sichuan Cancer Hospital. Primary endpoint: R0 resection rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sulumimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomametastatic malignant neoplasm in lymph node (LNM)oligometastatic disease (OMD)
Beyond the preview
Go deeper on ChiCTR2600123343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123343.